アルファ1アンチトリプシニンは,エムフィゼマ患者さんの肝臓に
まとめ
アルファ-1-アンチトリプシン欠乏症のエンフィゼマ患者における肝細胞は,異常なグリコプロテイン球を蓄積する. これは,血清欠乏にもかかわらず,分子の問題が,肝細胞からアルファ-1-アンチトリプシンが適切に放出されることを妨げることを示唆しています.
科学分野:
- 肝臓病理学 肝臓病理学
- 肺内科 肺内科 肺内科
- 遺伝学 遺伝学とは
背景:
- アルファ-1-アンチトリプシン欠乏症は遺伝性疾患であり,しばしばエムフィゼマを引き起こす.
- この欠乏症を有する患者は,アルファ-1-アンチトリプシンの低血清レベルを示します.
- アルファ-1-アンチトリプシン生成と潜在的機能障害における肝臓の役割は完全に理解されていません.
研究 の 目的:
- リンパ腫と遺伝性リンパ1抗トリプシン欠乏症の患者の肝細胞におけるアルファ-1-抗トリプシンの存在と特性を調査する.
- 肝細胞内にアルファ-1-アンチトリプシンが蓄積する潜在的な理由を探る.
主な方法:
- エムフィゼマ患者からの肝臓生検のヒストロジック検査.
- アルファ-1-アンチトリプシンを検出するための免疫光染色.
- 定期的な酸-シフ (PAS) 染色は,アミラーゼ処理と組み合わせた.
- 電子顕微鏡. 電子顕微鏡.
主要な成果:
- パレンキマ性肝細胞には,アルファ-1-アンチトリプシンに対する抗体と結合するグリコプロテインの球粒が含まれています.
- これらの球体は,標準的な染色法 (ヘマトキシリンとエオシン) と電子顕微鏡で観測できます.
- アミラゼで処理された部分のPAS染色は,これらの球球をより容易に示します.
- アルファ-1-アンチトリプシンが肝細胞内で高濃度に見られ,低血清濃度とは対照的です.
結論:
- アルファ-1-アンチトリプシン欠乏症とエムフィゼマの個体における肝細胞は,異常なアルファ-1-アンチトリプシン堆積を蓄積する.
- アルファ-1-アンチトリプシンの遺伝子変異における分子欠陥または偏差は,肝細胞からアルファ-1-アンチトリプシンの分泌を損なう可能性があります.
- この細胞内保持は,肝臓病理と全身欠乏の両方に寄与します.
関連する概念動画
Breathing
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...


